| Literature DB >> 21245905 |
Scott M Nelson1, Debbie A Lawlor.
Abstract
BACKGROUND: The extent to which baseline couple characteristics affect the probability of live birth and adverse perinatal outcomes after assisted conception is unknown. METHODS ANDEntities:
Mesh:
Year: 2011 PMID: 21245905 PMCID: PMC3014925 DOI: 10.1371/journal.pmed.1000386
Source DB: PubMed Journal: PLoS Med ISSN: 1549-1277 Impact factor: 11.069
Figure 1Definition of eligible cohort and analysis sample.
IVF, In-vitro fertilisation, GIFT, gamete intra-fallopian tube transfer, ZIFT, zygote intra-fallopian tube transfer.
Associations of potential predictors for live birth following IVF.
| Characteristic | Categories | Univariable Odds Ratio of Live Birth (95% CI) | Multivariable |
|
| Maternal age (years) | 18–34 | 1 | 1 | <0.001 |
| 35–37 | 0.77 (0.75–0.79) | 0.78 (0.76–0.81) | ||
| 38–39 | 0.53 (0.51–0.55) | 0.53 (0.51–0.56) | ||
| 40–42 | 0.29 (0.28–0.30) | 0.29 (0.28–0.31) | ||
| 43–44 | 0.10 (0.09–0.12) | 0.10 (0.09–0.12) | ||
| 45–50 | 0.15 (0.12–0.19) | 0.12 (0.09–0.15) | ||
| Duration of infertility (years) | <1 | 1.48 (1.34–1.65) | 1.51 (1.35–1.68) | <0.001 |
| 1–3 | 1.10 (1.07–1.13) | 1.11 (1.08–1.15) | ||
| 4–6 | 1 | 1 | ||
| 7–9 | 0.91 (0.87–0.94) | 0.94 (0.91–0.98) | ||
| 9–12 | 0.81 (0.76–0.85) | 0.87 (0.82–0.92) | ||
| >12 | 0.71 (0.67–0.75) | 0.89 (0.84–0.95) | ||
| Cause of infertility | Unknown | 1 | 1 | <0.001 |
| Tubal only | 0.94 (0.90–0.97) | 0.87 (0.83–0.90) | ||
| Anovulatory only | 0.93 (0.88–0.98) | 0.95 (0.90–1.00) | ||
| Endometriosis only | 1.05 (0.98–1.13) | 0.96 (0.89–1.03) | ||
| Cervical only | 0.41 (0.20–0.85) | 0.39 (0.19–0.82) | ||
| Male only | 1.16 (1.13–1.20) | 0.91 (0.87–0.95) | ||
| Combination known causes | 1.01 (0.96–1.06) | 0.88 (0.83–0.92) | ||
| Number of previous unsuccessful IVF | 0 | 1 | 1 | <0.001 |
| 1 | 0.74 (0.70–0.79) | 0.72 (0.65–0.81) | ||
| 2 | 0.69 (0.64–0.76) | 0.70 (0.62–0.80) | ||
| 3 | 0.74 (0.66–0.84) | 0.77 (0.66–0.91) | ||
| 4 | 0.51 (0.42–0.62) | 0.55 (0.45–0.69) | ||
| ≥5 | 0.57 (0.48–0.69) | 0.68 (0.55–0.83) | ||
| Mutually exclusive categories of previous IVF and obstetric history | No previous IVF, 0 pregnancy | 1 | 1 | <0.001 |
| No previous IVF, at least 1 pregnancy, 0 live births | 0.88 (0.86–0.91) | 1.03 (0.99–1.06) | ||
| No previous IVF, at least 1 pregnancy, at least 1 live birth | 0.92 (0.88–0.96) | 1.19 (1.14–1.24) | ||
| Previous IVF, 0 pregnancy | 0.72 (0.68–0.76) | 1.14 (1.01–1.28) | ||
| Previous IVF, at least 1 pregnancy, 0 live birth | 0.68 (0.64–0.73) | 1.02 (0.93–1.11) | ||
| Previous IVF, at least 1 pregnancy, at least 1 live birth | 1.10 (1.03–1.17) | 1.58 (1.46–1.71) | ||
| Hormonal preparation | Antioestrogen | 1 | 1 | <0.001 |
| Gonadatrophin | 1.43 (1.24–1.63) | 1.33 (1.15–1.53) | ||
| Hormone replacement | 1.61 (1.38–1.89) | 1.55 (1.31–1.82) | ||
| Cycle number | 1 | 1 | 1 | <0.001 |
| 2 | 0.80 (0.78–0.83) | 0.85 (0.82–0.87) | ||
| ≥3 | 0.76 (0.74–0.79) | 0.88 (0.85–0.91) | ||
| Source of egg | Donor | 1 | 1 | <0.001 |
| Patient | 0.87 (0.74–1.02) | 0.38 (0.32–0.45) | ||
| Treatment type | IVF | 1 | 1 | <0.001 |
| ICSI plus IVF | 1.28 (1.25–1.31) | 1.27 (1.23–1.31) |
N = 144,018 analysis cohort with complete data on all variables included in any model.
Multivariable adjusted = mutual adjustment for all variables listed in column one.
p-Value for multivariable association; all p-values are likelihood ratio tests of null hypothesis that the odds are the same for each category (i.e., they do not assume linearity).
AUROC for the Templeton and novel method of predicting live birth with IVF.
| Model | AUROC (95% Confidence Interval) |
|
| Templeton | 0.6184 (0.6152–0.6217) | ref |
| Novel model | 0.6335 (0.6202–0.6367) | <0.001 |
N = 144,018 analysis cohort with complete data on all variables included in any model. Templeton: As in reference [7], to date the only externally validated prediction model. Novel model: using the same variables as Templeton but allowing them to have different multivariable coefficients to those originally derived by Templeton and including terms for all causes of infertility (rather than just tubal versus other, as in the original Templeton) and four additional predictors: type of hormonal preparation, whether egg came from patient or donor, number of treatment cycles, and whether ICSI was used with the IVF.
Figure 2Ratios of predicted to observed live birth rate using two prediction models.
N = 144,018 cycles of IVF treatment in the United Kingdom. Long dashed line, Templeton model; short dashed line, novel prediction model 2; red horizontal line, ratio of 1 (i.e., perfect prediction) for all levels of risk.
Calibration of the two prediction models.
| Tenth of the Distribution of the Linear Predictor | Templeton Prediction Model | Novel Prediction Model | ||||
| Observed Live Birth Rate per 100 Cycles of Treatment (95% CI) | Predicted Live Birth Rate per 100 Cycles of Treatment (95% CI) | Ratio Predicted to Observed | Observed Live Birth Rate per 100 Cycles of Treatment (95%CI) | Predicted Live Birth Rate per 100 Cycles of Treatment (95%CI) | Ratio Predicted to Observed | |
| Lowest 10th | 8.36(7.91–8.81) | 3.57(3.54–3.59) | 0.43 | 7.66(7.23–8.09) | 7.23(7.18–7.28) | 0.94 |
| 2nd | 13.66(13.10–14.22) | 6.44(6.43–6.45) | 0.47 | 13.21(12.66–13.76) | 13.16(13.13–13.18) | 1.00 |
| 3rd | 18.67(18.04–19.29) | 8.45(8.43–8.46) | 0.45 | 18.15(17.53–18.78) | 18.00(17.99–18.02) | 1.00 |
| 4th | 22.77(22.14–23.40) | 10.26(10.25–10.26) | 0.45 | 20.42(19.76–21.08) | 21.10(21.09–21.11) | 1.03 |
| 5th | 23.30(22.51–24.07) | 11.61(11.60–11.62) | 0.50 | 23.40(22.71–24.08) | 23.63(23.62–23.63) | 1.01 |
| 6th | 25.41(24.77–26.05) | 13.31(13.30–13.32) | 0.52 | 24.87(24.18–25.56) | 25.57(25.57–25.59) | 1.03 |
| 7th | 29.93(29.22–30.64) | 13.69(13.69–13.69) | 0.46 | 27.04(26.30–27.77) | 27.43(27.42–27.44) | 1.01 |
| 8th | 26.78(25.87–27.67) | 14.77(14.76–14.78) | 0.55 | 30.37(29.62–31.12) | 29.35(29.34–29.36) | 0.97 |
| 9th | 31.85(31.21–32.50) | 17.29(17.28–17.30) | 0.54 | 32.26(31.54–32.98) | 31.95(31.94–31.97) | 0.99 |
| Highest 10th | 33.26(32.23–34.22) | 20.91(20.84–20.98) | 0.63 | 36.50(35.66–37.34) | 36.47(36.43–35.61) | 1.00 |
N = 144,018 analysis cohort with complete data on all variables included in any model. The cohort is split into 10ths of the distribution of the linear predictor for each of the two prediction models. For example, for the Templeton prediction model the observed and predicted are compared by 10th of the Templeton linear predictor.
Templeton: As in reference [7], to date the only externally validated prediction model (Text S1).
Novel model: Using the same variables as Templeton but allowing them to have different multivariable coefficients to those originally derived by Templeton and including terms for all causes of infertility (rather than just tubal versus other as in the original Templeton) and four additional predictors: type of hormonal preparation, whether egg came from patient or donor, number of treatment cycles, and whether ICSI was used with the IVF (Text S2).
Examples of risk prediction in women.
| Example Couples | Estimate of Probability of Live Birth after IVF per 100 Cycles |
| A. The woman is 40 y old and the couple have been trying to conceive for over 11 y. They have had four previous unsuccessful IVF treatments (two of which resulted in pregnancy but not a live birth). The couple's cause of infertility is a male problem and they have been treated with ICSI. They are now wishing to embark on their fifth treatment cycle. The woman's own oocytes will be used and the hormonal preparation is gonadotrophin. | 4.8/100 cycles |
| B. If we take the same couple as in A but change the treatments so that a donor oocyte is used and the hormonal preparation is hormone replacement (all other characteristics stay the same as in A) | 16.7/100 cycles |
| C. The woman is 33 and the couple started trying to conceive 5 y ago after the live birth of their son, which was a spontaneous pregnancy. The couple's cause of infertility is unknown. They will not be treated with ICSI; the woman's own oocytes will be used and the hormonal preparation will be gonadotrophins. This will be their first treatment cycle. | 29.8/100 cycles |
| D. If we take the same couple as in C but change the treatments so that ICSI will be used, with a donor oocyte and hormone replacement as the hormonal preparation (all other characteristics stay the same as in A). | 43.5/100 cycles |
These examples are plausible in terms of the types of patients regularly seen in IVF clinics, and they show the influence of couple characteristics (compare A to C and B to D) and of treatment effects (compare B to A and D to C), and of both of these combined (compare D to A).
Multivariable associations of potential risk factors with preterm birth, low birth weight and macrosomia amongst singleton births following IVF.
| Characteristic | Categories | Multivariable Association with Preterm Birth; | Multivariable Association with Low Birth Weight; | Multivariable Association with Low Birth Weight; | |||
| Odds Ratio (95%CI) |
| Odds Ratio (95%CI) |
| Odds Ratio (95%CI) |
| ||
| Age, y | 18–34 | 1 | 0.12 | 1 | 0.04 | 1 | 0.01 |
| 35–37 | 0.90 (0.80–1.00) | 0.87 (0.78–0.97) | 1.14 (1.03–1.27) | ||||
| 38–39 | 0.87 (0.75–1.00) | 0.86 (0.74–0.99) | 1.09 (0.95–1.25) | ||||
| ≥40 | 0.93 (0.77–1.10) | 0.96 (0.80–1.15) | 1.25 (1.06–1.48) | ||||
| Duration of infertility, y | <1 | 1.05 (0.73–1.49) | 0.004 | 0.86 (0.58–1.25) | 0.01 | 0.81 (0.56–1.17) | 0.20 |
| 1–3 | 0.96 (0.86–1.07) | 0.90 (0.80–1.00) | 0.90 (0.81–0.99) | ||||
| 4–6 | 1 | 1 | 1 | ||||
| 7–9 | 1.17 (1.02–1.35) | 1.07 (0.93–1.24) | 1.02 (0.89–1.16) | ||||
| ≥9 | 1.25 (1.07–1.46) | 1.16 (1.00–1.36) | 0.93 (0.80–1.09) | ||||
| Cause | Unknown | 1 | <0.001 | 1 | 0.02 | 1 | 0.002 |
| Tubal only | 1.22 (1.06–1.41) | 1.12 (0.97–1.30) | 1.06 (0.91–1.22) | ||||
| Anovulatory only | 1.14 (0.95–1.37) | 1.19 (1.00–1.42 | 1.04 (0.86–1.25) | ||||
| Endometriosis only | 0.86 (0.65–1.14) | 1.04 (0.80–1.35) | 0.96 (0.73–1.25) | ||||
| Cervical only | 9.09 (2.01–41.13) | 15.62 (2.59–94.06) | 10.46 (1.46–74.85) | ||||
| Male only | 0.95 (0.83–1.09) | 1.02 (0.89–1.17) | 1.22 (1.07–1.39) | ||||
| Combination known causes | 1.19 (1.00–1.41) | 1.15 (0.97–1.36) | 0.92 (0.77–1.11) | ||||
| Previous unsuccessful IVF, number | 0 | 1 | 0.44 | 1 | 0.37 | 1 | 0.95 |
| 1 | 0.75 (0.50–1.15) | 0.85 (0.56–1.29) | 0.92 (0.77–1.10) | ||||
| 2 | 0.80 (0.50–1.30) | 0.82 (0.51–1.32) | 0.92 (0.61–1.38) | ||||
| ≥3 | 0.66 (0.40–1.11) | 0.63 (0.38–1.06) | 0.98 (0.61–1.58) | ||||
| Mutually exclusive categories of previous IVF and obstetric history | No previous IVF, 0 pregnancy | 1 | 0.11 | 1 | 0.004 | 1 | <0.001 |
| No previous IVF, at least 1 pregnancy, 0 live births | 1.15 (0.40–1.11) | 1.13 (1.00–1.27) | 1.23 (1.09–1.39) | ||||
| No previous IVF, at least 1 pregnancy, at least 1 live birth | 0.99 (0.84–1.16) | 0.83 (0.70–0.98) | 1.28 (1.11–1.49) | ||||
| Previous IVF, 0 pregnancy | 1.48 (0.95–2.30) | 1.54 (1.00–2.39) | 0.97 (0.63–1.49) | ||||
| Previous IVF, at least 1 pregnancy, 0 live birth | 1.30 (0.93–1.80) | 1.37 (0.99–1.91) | 1.02 (0.72–1.43) | ||||
| Previous IVF, at least 1 pregnancy, at least 1 live birth | 1.02 (0.55–1.38) | 0.89 (0.67–1.17) | 1.30 (1.03–1.63) | ||||
| Hormonal preparation | Antioestrogen | 1 | 0.11 | 1 | 0.77 | 1 | 0.86 |
| Gonadatrophin | 0.87 (0.55–1.39) | 1.18 (0.71–1.97) | 1.08 (0.64–1.83) | ||||
| Hormone replacement | 1.07 (0.63–1.82) | 1.24 (0.69–2.21) | 1.15 (0.64–2.07) | ||||
| Cycle number | 1 | 1 | 0.43 | 1 | 0.17 | 1 | 0.04 |
| 2 | 1.00 (0.89–1.13) | 0.96 (0.85–1.08) | 1.07 (0.96–1.20) | ||||
| ≥3 | 0.92 (0.81–1.05) | 0.89 (0.78–1.01) | 1.17 (1.04–1.31) | ||||
| Source of egg | Donor | 1 | <0.001 | 1 | <0.001 | 1 | 0.16 |
| Patient | 0.41 (0.26–0.64) | 0.42 (0.26–0.68) | 0.68 (0.39–1.17) | ||||
| Treatment type | IVF | 1 | 0.05 | 1 | 0.05 | 1 | 0.46 |
| IVF and ICSI | 0.89 (0.80–1.00) | 0.89 (0.80–1.00) | 0.96 (0.86–1.07) | ||||
Cycles included in analyses are from couples for whom data were complete on all variables and who experienced a singleton birth after IVF. For associations with low birth weight, those with macrosomia as an outcome are removed so that low birth weight is compared with normal birth weight, and similarly for macrosomia, those with low birth weight are removed so that macrosomia is compared with normal birth weight. The results are with mutual adjustment for all variables in the first column. In addition, for preterm birth, results are adjusted for mean birth weight and for low birth weight and macrosomia for mean gestational age. p-Values are likelihood ratio tests of null hypothesis that the odds are the same for each category (i.e., they do not assume linearity).